Reslizumab (Cinqair)

OFFICE ADMININSTRATION

Indications for Prior Authorization: 

  • Severe Eosinophilic Asthma

All of the following must be met as a condition(s) for coverage:

  • Must be prescribed AND followed by a pulmonologist or immunologist, AND
  • Patient must be at least 18 years of age, AND
  • Eosinophil blood count of 150 cells µL within last 6 weeks or ≥ 300 cells/µL within the last 12 months, AND 
  • Patient had inadequate response to a high-dose inhaled corticosteroid in combination with long-acting beta agonist [LABA] and has been compliant with therapy for at least 3 months, AND
  • Patient meets one of the following within the past year:
    • One or more acute asthma-related ED visit(s)
    • One or more acute inpatient visits where asthma was the principle diagnosis
    • Use of chronic systemic steroids due to severe asthma OR two or more acute asthma exacerbations requiring oral systemic steroids AND
  • Will not be used in combination with Xolair (omalizumab), or Nucala (mepolizumab), AND
  • Patient is not a current smoker

Patients for whom therapy with reslizumab is not indicated include:

  • Combination use with Omalizumab (Xolair) or Nucala (mepolizumab)
  • Monotherapy use
  • Patients with Chronic Obstructive Pulmonary Disease (COPD)
  • Treatment of other eosinophilic conditions
  • Relief of acute bronchospasm or status asthmaticus

Dosing:

Adult

  • IV infusion: 3 mg/kg every 4 weeks by IV infusion over 20-50 minutes (asminister in healthcare setting by a healthcare professional prepared to manage anaphylaxis)

Younger than 18 years

  • Safety and efficacy have not been established

Approval:

  • Initially for 24 weeks (6 months)
  • Re-Authorization consideration for 1 year (after initial 24 weeks) of therapy if the following criteria are met
    • Prescribed by a pulmonologist or immunologist, AND
    • Patient is continually compliant with all asthma medications, AND
    • Response to treatment with reslizumab (Cinqair), as evidenced by at least one of the following [must be documented in the medical record]:
      • Reduction in asthma symptoms (e.g., decreased number of sick days, improvement in physical activity, reduction in "as needed" use of short acting beta agonists), OR
      • Reduction in dose and frequency of inhaled steroids compared to baseline, OR
      • Reduction in acute asthma exacerbations requiring oral systemic steroids
  • Subsequent re-Authorization consideration - yearly if all of the following criteria are met
    • Prescribed by a pulmonologist or immunologist, AND
    • Patient is continually compliant with all asthma medications, AND
    • Continued response to treatment with reslizumab (Cinqair), as documented by at least one of the following [must be documented in the medical record]:
      • Stable or reduced asthma symptoms (e.g., no increase in number of sick days, decrease in physical activity, increase in "as needed" use of short acting beta agonists), OR
      • Stable or reduced (but not discontinued) dose and frequency of inhaled steroids compared to baseline, OR
      • Stable or reduced asthma exacerbations requiring oral systemic steroids

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar